MedTech News
.................... by Andrew Celentano
Year-old brain organoids reveal astrocytes may fuel early-onset epilepsy
Tiny, year-old human brain organoids that mimic the brain of a newborn are providing new clues to potential treatments for a leading genetic cause of childhood epilepsy that typically manifests as the brain matures shortly after birth.
Cancer’s ‘rogue DNA’ relies on two proteins to prevent and repair breaks
Researchers at Memorial Sloan Kettering Cancer Center (MSK) and their colleagues have discovered that a type of rogue DNA found in aggressive cancers has a hidden structural weakness—and that blocking a single repair protein can cause it to fall apart, suggesting a new therapeutic opportunity.
New filters help genetic sequencing flag possible causes of meningitis and encephalitis
New research led by Aston University’s Dr. Ghaniah Hassan-Smith has found a new way to diagnose infections of the central nervous system, such as meningitis and encephalitis, that can be difficult to identify using conventional methods.
A simple pill could prevent sight loss in diabetes-driven eye condition, early findings suggest
Researchers at Trinity College Dublin, in collaboration with Breye Therapeutics, have found that an oral medication (“Danegaptide”) can protect against vision-threatening damage in nonproliferative diabetic retinopathy (NPDR), a leading cause of blindness in working-age adults.
Newly discovered inflammatory cell signaling could open the door to autoimmune disease treatments
Our understanding of how cells interact with each other has been driven for decades by the central concept of receptor-mediated signal transduction. Now, researchers from Boston Children’s Hospital are reporting the discovery of a new, receptor-free means of signal transduction.
Computer-designed T-cell receptors boost attacks on cancer and viral targets in early tests
A joint team of researchers at Bar-Ilan University and the Weizmann Institute has used advanced computational design methods to enhance the ability of genetically engineered immune cells to recognize and attack cancer and viral targets.
Experimental drug reverses paralysis and vision loss in multiple sclerosis model
A drug developed by a UVA Health scientist has not only stopped but reversed paralysis and vision loss in a mouse model of multiple sclerosis. The results are striking because existing MS treatments are designed to reduce future inflammatory attacks, not restore neurological function already lost.
Werfen Announces US FDA 510(k) Clearance and CE Mark for Aptiva® Antiphospholipid Syndrome IgA Reagent
FDA Clearance and CE Mark Complete Aptiva’s Antiphospholipid Syndrome Portfolio, Expanding Global Access to Comprehensive APS Testing